Comparative Pharmacology
Head-to-head clinical analysis: DYNAPEN versus PENICILLIN G SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNAPEN versus PENICILLIN G SODIUM.
DYNAPEN vs PENICILLIN G SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dynapen (dicloxacillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg orally every 6 hours for skin and soft tissue infections; up to 500 mg every 6 hours for respiratory tract infections.
2-4 million units intravenously every 4 hours for moderate to severe infections; up to 24 million units/day for severe infections (e.g., meningitis, endocarditis).
None Documented
None Documented
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria.
30-60 minutes in normal renal function; prolonged to 7-10 hours in anuria.
Renal: 60-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <10%.
Primarily renal (60-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (<10%).
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic